Endostar can normalize tumor vasculature, inhibits tumor angiogenesis, endothelial cell proliferation and migration via downregulating a number of angiogenic factors including VEGF.2, 3, 4 In clinical trials of Endostar in combination with traditional chemotherapy for advanced NSCLC, Endostar significantly improved the outcome in patients, demonstrating an antitumor effect.5 Here, VEGFA is linked to neoplasm.